INTRODUCTION
I n recent years there has been an upsurge of interest in the coordination chemistry of technetium, largely due to the widespread use of the short-lived 99mTc isotope (tl 2 6 h) in diagnostic nuclear medicine. Much work has been directed towards the deve{op;ent of new organ-specific radiopharmaceuticals, in particular for brain and heart imaging (ref. 1) . The use of the long-lived 99Tc isotope (t1/2 = 2.12 x 105 years) allows technetium compounds to be isolated and studied by conventional chemical and spectroscopic techniques. Complexes based on the [TcV0]3+ core are common and are of importance in nuclear medicine (ref. 1). The nitrido ligand (N3-) is isoelectronic with the 0x0 ligand (Oz-) and is a powerful n-electron donor which stabilises transition metals in high oxidation states. The TEN bond has been shown to be remarkably resistant to hydrolysis and to form the basis of an extensive chemistry, particularly i n the +5 oxidation state. 
5). cm-1 i n d i c a t i n g t h a t t h e product i s probably a polymeric 0x0-bridged hydrate. N i t r i d o t e c h n e t i c ( V 1 ) a c i d has proved t o be a u s e f u l s t a r t i n g m a t e r i a l , p a r t i c u l a r l y i n cases where competition by c h l o r i d e i s t o be avoided. i n 50 percent HF have been shown by e.5.r. spectroscopy t o c o n t a i n [TcNF4]-, [TcNC14]-and t h e t h r e e mixed species. Solutions o f n i t r i d o t e c h n e t i c ( V 1 ) a c i d i n
t o g i v e a y e l l o w s o l u t i o n . e l e c t r o p h o r e s i s u s i n g 0.5 M HPTS as t h e supporting e l e c t r o l y t e has shown t h e presence a s i n g l e c a t i o n i c species and t h e absence o f any n e u t r a l o r anionic species. evidence f o r t h e presence o f a technetium n i t r i d o a q u a c a t i o n i n s o l u t i o n . o f t h i s c a t i o n i s being i n v e s t i g a t e d .
